InflaRx N.V. (IFRX) stock
Close on Nov 12, 2026Market cap $89.64MP/E –Yield –
InflaRx N.V. saw revenue fall 82.3% to €29.33K over fiscal 2025. At the latest close the market valued the company at €80.37M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €80.37M
- P/E ratio
- –
- Price to sales
- 2740.05
- Price to book
- 11.21
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €29.33K
- EPS, diluted
- -0.68 EUR
Trading
- Previous close
- $1.18
- Open
- $1.21
- Day's range
- $1.15 – $1.25
- Volume
- 883,021
- Average volume (20 days)
- 1,136,697
- Beta (5 years)
- 1.47
- RSI (14 days)
- 29.1
- Volatility (1 year)
- 88.9%
- Relative volume
- 0.66×
- WACC
- 12.3%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IFRX | S&P 500 | Difference | IFRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.0% | -2.7% | −19.3 pts | ||
| 3 months | -38.3% | -1.7% | −36.6 pts | ||
| Year to date | +22.8% | +11.9% | +10.9 pts | ||
| 1 year | -15.1% | +12.0% | −27.1 pts | ||
| 3 years | -3.1% | +78.2% | −81.3 pts | -1.1% | +21.2% |
| 5 years | -77.8% | +73.2% | −151.0 pts | -26.0% | +11.6% |
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
Gross profit
Operating income
EPS, diluted
Press releases
Releases InflaRx filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About InflaRx
Pharmaceutical Preparations
InflaRx N.V. is a biopharmaceutical company that discovers and develops treatments for complement-mediated inflammatory and immunological diseases. The company utilizes proprietary anti-C5a and anti-C5aR technologies to target debilitating conditions. Its primary product is vilobelimab, marketed as GOHIBIC, which holds emergency use authorization in the United States and marketing authorization in Europe for treating severe COVID-19. InflaRx also develops vilobelimab for additional inflammatory indications, alongside pipeline candidates including izicopan and IFX002. These therapies target patients suffering from severe immune disorders and the healthcare systems that treat them.
Company profile, executives and historyInflaRx stock: common questions
What is InflaRx's stock price?
IFRX closed at $1.24 on Nov 12, 2026, up 5.08% on the day.
What is InflaRx's market cap?
InflaRx was worth $89.64M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IFRX's P/E ratio?
InflaRx lost money over fiscal 2025 (diluted EPS -0.68 EUR), so it has no meaningful P/E ratio.
How much revenue does InflaRx make?
InflaRx reported revenue of €29.33K for fiscal 2025, down 82.3% from a year earlier.
Does InflaRx pay a dividend?
No. InflaRx has not paid a cash dividend over the last twelve months.
How has IFRX stock performed over the past year?
Including dividends, IFRX returned -15.1% over the past year, against +12.0% for the S&P 500.
Who are InflaRx's competitors?
Companies most similar to InflaRx by business, industry and size include KPRX, AVTX, IBO, ADXN, ALT.
See a number that looks wrong?